Collegium Announces $25 Million Accelerated Share Repurchase Program

Rhea-AI Summary

Collegium Pharmaceutical (Nasdaq: COLL) announced a $25 million Accelerated Share Repurchase (ASR) agreement with Jefferies LLC, part of a larger $100 million share buyback program authorized in August 2021. Upon completion of this ASR, Collegium will have approximately $52.2 million remaining under the buyback authorization. The ASR involves repurchasing around 1,026,694 shares at the $19.48 closing stock price as of November 12, 2021. This move reflects management's confidence in the business and commitment to enhancing shareholder value.

Positive

• Initiation of a $25 million ASR demonstrates strong financial positioning and commitment to shareholder value.
• Management's confidence highlighted by the completion of the ASR as part of a $100 million buyback program.

Negative

• None.

STOUGHTON, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $25 million of the Company’s common stock. Collegium will execute the ASR as part of the $100 million share repurchase program authorized by its Board of Directors in August 2021. Upon completion of this ASR, Collegium will have $52.2 million remaining under the authorization.

“Today’s announcement of the accelerated share repurchase program reinforces our confidence in the business and our commitment to deliver value to our shareholders through effective deployment of our balance sheet,” said Joe Ciaffoni, President and Chief Executive Officer of Collegium. “We believe that our strong financial position gives us the ability to return cash to shareholders, execute on our business strategy and invest in our long-term growth.”

Under terms of the agreement, Collegium will pay $25 million to Jefferies LLC and will receive approximately 1,026,694 shares, based on the $19.48 closing stock price of Collegium’s common stock on November 12, 2021, representing approximately 80% of the total shares the Company expects to repurchase under the ASR agreement. The final number of shares repurchased will be based on the volume-weighted average prices of Collegium’s common stock during the term of the transaction, and subject to adjustments related to the terms and conditions of the ASR agreement and is expected to be completed in the first quarter of 2022. As of September 30, 2021, Collegium had approximately 34.8 million shares outstanding.

About Collegium Pharmaceutical, Inc.

Collegium is a specialty pharmaceutical company committed to being the leader in responsible pain management. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at www.collegiumpharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements regarding financial guidance for Xtampza ER and Nucynta Franchise revenues, Adjusted EBITDA, total operating expenses, current and future market opportunities for our products and our assumptions related thereto. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results, performance, or achievements to differ materially from the company's current expectations. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the impact of the COVID-19 pandemic on our ability to conduct our business, reach our customers, and supply the market with our products; our ability to commercialize and grow sales of our products; our ability to manage our relationships with licensors; the success of competing products that are or become available; our ability to obtain and maintain regulatory approval of our products and any product candidates, and any related restrictions, limitations, and/or warnings in the label of an approved product; the size of the markets for our products and product candidates, and our ability to service those markets; our ability to obtain reimbursement and third-party payor contracts for our products; the rate and degree of market acceptance of our products and product candidates; the costs of commercialization activities, including marketing, sales and distribution; changing market conditions for our products; the outcome of any patent infringement, opioid-related or other litigation that may be brought by or against us, including litigation with Purdue Pharma, L.P.; the outcome of any governmental investigation related to our business; our ability to secure adequate supplies of active pharmaceutical ingredient for each of our products and manufacture adequate supplies of commercially saleable inventory; our ability to obtain funding for our operations and business development; regulatory developments in the U.S.; our expectations regarding our ability to obtain and maintain sufficient intellectual property protection for our products; our ability to comply with stringent U.S. and foreign government regulation in the manufacture of pharmaceutical products, including U.S. Drug Enforcement Agency, or DEA, compliance; our customer concentration; and the accuracy of our estimates regarding expenses, revenue, capital requirements and need for additional financing. These and other risks are described under the heading "Risk Factors" in our Quarterly Report on Form 10-Q and other filings with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

FAQ

What is the purpose of Collegium Pharmaceutical's $25 million share buyback?

The $25 million share buyback aims to enhance shareholder value and reflects the company's strong financial position.

How many shares is Collegium Pharmaceutical repurchasing in the ASR agreement?

Collegium is repurchasing approximately 1,026,694 shares under the ASR agreement.

What is the remaining amount under Collegium's share repurchase authorization after the ASR?

After the ASR, Collegium will have approximately $52.2 million remaining under the share repurchase authorization.

When is the ASR agreement expected to be completed?

The ASR agreement is expected to be completed in the first quarter of 2022.